785 related articles for article (PubMed ID: 35081305)
1. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
2. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
4. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects.
Klein B; Treudler R; Simon JC
J Dtsch Dermatol Ges; 2022 Jan; 20(1):19-24. PubMed ID: 34962052
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
Muddebihal A; Khurana A; Sardana K
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
7. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
8. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
9. Topical Janus kinase inhibitors: A review of applications in dermatology.
Hosking AM; Juhasz M; Mesinkovska NA
J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
[TBL] [Abstract][Full Text] [Related]
10. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
11. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.
Samuel C; Cornman H; Kambala A; Kwatra SG
Dermatol Ther (Heidelb); 2023 Mar; 13(3):729-749. PubMed ID: 36790724
[TBL] [Abstract][Full Text] [Related]
12. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
13. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
14. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W; King BA
J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
Dogra S; Sharma A; Mehta H; Sarkar R
Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
18. Application of Baricitinib in Dermatology.
Zhang J; Qi F; Dong J; Tan Y; Gao L; Liu F
J Inflamm Res; 2022; 15():1935-1941. PubMed ID: 35330989
[TBL] [Abstract][Full Text] [Related]
19. JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety.
Elmariah SB; Smith JS; Merola JF
Am J Clin Dermatol; 2022 Jul; 23(4):427-431. PubMed ID: 35679017
[TBL] [Abstract][Full Text] [Related]
20. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?].
von Martial S; Tsianakas A
Dermatologie (Heidelb); 2024 Mar; 75(3):256-267. PubMed ID: 38100043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
